Development and validation of multivariable biopsy-free nomograms to predict clinically significant prostate cancer in patients with prostate-specific antigen levels ≥20 ng/mL.

ABSTRACT:

Background

Elevated prostate-specific antigen (PSA) levels often lead to prostate biopsies, which can result in overdiagnosis and complications, thereby increasing preoperative anxiety. This study aimed to develop and validate a novel biopsy-free diagnostic nomogram for accurate detection of clinically significant prostate cancer (csPCa) in patients with PSA levels ≥20 ng/mL.

Methods

The cohort of this retrospective analysis included patients with PSA levels ≥20 ng/mL who underwent evaluation including clinical variables, Prostate Imaging-Reporting and Data System (PI-RADS), prostate health index (PHI), and prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET/CT). Nomogram performance was evaluated using the concordance index, calibra

SUBMITTER: Chen M 

PROVIDER: S-EPMC11986468 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature